Yunkang Group (2325) H2 2023 earnings summary

Executive summary

• FY2023 revenue fell 76.3% YoY to RMB891.5m as nationwide demand for phased testing and screening declined; routine testing grew steadily excluding that impact.

• Net loss was RMB101.9m versus net profit of RMB373.9m in 2022, reflecting lower revenue, increased receivables impairment and one-off redundancy costs.

• Gross margin improved to 36.5% from 34.8%, supported by cost control and stronger operating management.

Financial highlights

• Gross profit declined 75.1% YoY to RMB325.8m; operating loss was RMB52.6m versus operating profit of RMB458.6m in 2022.

• Loss before tax was RMB86.8m; net loss was RMB101.9m and loss attributable to owners was RMB102.3m.

• Basic and diluted loss per share was RMB0.17, versus earnings per share of RMB0.66 in 2022.

• Net impairment losses on financial assets were RMB104.6m, mainly provisions for trade receivables; net finance costs rose to RMB34.2m from RMB15.1m.

Outlook and guidance

• 2024 priorities include deepening customer and hospital partnerships, expanding market coverage, improving jointly operated laboratory performance and increasing R&D investment in precision medicine and intelligent testing.

• Plans include an end-to-end laboratory digital platform over two to three years and further development of AI-assisted genetic sequencing and pathology diagnostics.

• Management expects third-party diagnostic services to benefit from healthcare cost control, wider ICL adoption and demand for technology-enabled testing; no numerical financial guidance was stated.